-
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
19 Dec 2025 21:00 GMT
… HCM. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator …
-
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
19 Dec 2025 16:35 GMT
… function, with a pipeline including omecamtiv mecarbil (cardiac myosin activator), reldesemtiv (skeletal …
-
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
17 Dec 2025 12:30 GMT
… 2026. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in …
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
16 Dec 2025 21:00 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in … , Facebook and YouTube. Disclaimer Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are …
-
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
12 Dec 2025 13:42 GMT
… . In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in … , Facebook and YouTube. Disclaimer Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are …
-
Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
03 Dec 2024 12:30 GMT
… the trial. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, … has shown that omecamtiv mecarbil increases cardiac contractility … omecamtiv mecarbil, demonstrated a statistically significant effect of treatment with omecamtiv mecarbil …
-
Human medicines European public assessment report (EPAR): Kinharto, Omecamtiv mecarbil, Date of refusal: 07/05/2024, Status: Withdrawn application
31 May 2024 14:36 GMT
Based on the review of the data and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency had concerns and its provisional opinion was that Kinharto could not be authorised for the treatment of chronic (long-term) …
-
Chronic Heart Failure Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight
25 Nov 2025 18:00 GMT
… heart failure therapies, such as Omecamtiv mecarbil, Vicadrostat (BI690517) + Empagliflozin, Ziltivekimab, Revascor … Chronic Heart Failure Pipeline Therapies: Omecamtiv mecarbil, Vicadrostat (BI690517) + Empagliflozin, Ziltivekimab, Revascor …
-
FDA Declines Approval for Omecamtiv Mecarbil in HFrEF
01 Mar 2023 20:08 GMT
… advisers recommended against approval of omecamtiv mecarbil for chronic HFrEF, as reported … by theheart.org | Medscape Cardiology, omecamtiv mecarbil produced a positive result for … an additional clinical trial of omecamtiv mecarbil are required to establish …
-
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
28 Feb 2023 22:31 GMT
… Drug Application (NDA) for omecamtiv mecarbil, an investigational, selective, … access the call. About Omecamtiv Mecarbil Omecamtiv mecarbil is an investigational, selective, … research has shown that omecamtiv mecarbil increases cardiac contractility without …
About
© 1995-2025